Infusion Drug Delivery Videos

  1. Drug Delivery Technology Adoption: A Case Of Too Many Options? 5/23/2025

    In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, uses the case of Enbrel® and the multiple delivery options for it to illustrate patient considerations and market factors that can impact product success.

  2. Defining and Regulating Combination Products: An Evolutionary Journey 10/15/2024

    In this episode of The Combination Products Handbook: The Series, host Tom von Gunden discusses Chapter 1 of The Combination Products Handbook: A Practical Guide for Combination Products and Other Combined Use Systems (CRC Press, 2023) with the book’s editor, Susan Neadle. Given that the initial chapter was penned by the FDA’s John “Barr” Weiner, the discussion focuses on reasons for establishing the historical and regulatory context for combination products early in the handbook’s topic coverage.

  3. Drug Delivery Market Success: Lessons From A Discontinued Product 5/23/2025

    In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, host Fran DeGrazio and James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, ponder the discontinuation of Repatha® Pushtronex®. They comment on how its withdrawal may illustrate key market drivers and factors that bolster a product’s success or, alternatively, lead to its demise.

  4. Leveraging Janus Base Nanoparticles For Precision Therapeutic Delivery With Eascra's Mari Anne Snow 10/31/2025

    A major challenge in delivering biologics-based therapies is penetrating cells for precision delivery to therapeutic targets. In this episode of Supplier Horizons, host Tom von Gunden and CEO Mari Anne Snow from platform technology developer Eascra Biotech discuss the use of Janus base nanoparticles to effectively and safely encapsulate therapeutic payloads, including CGTs and other large molecule biologics. The conversation also turns to the benefits of particle production conducted in space. 

  5. Knowing How Injection Volumes Impact Delivery Options 2/17/2026

    In this segment of the Drug Delivery Leader Live online event, Injected, Infused, or Implanted: A Penetrating Look At Patient Centricity, Chief Editor Tom von Gunden relays an audience question about how to decide if injection volumes dictate delivery via prefilled syringe versus autoinjector.

  6. Identifying EDDOs During Drug Delivery Device Design 10/9/2024

    How are EDDOs (Essential Drug Delivery Outputs) determined during the design of a drug-led or biologic-led combination product? In this segment of the Drug Delivery Leader Live event The FDA Guidance on EDDO: What to Know, What to Do, consultant Susan Neadle of Combination Products Consulting Services, LLC lays out the foundational considerations.

  7. Protecting And Sustaining Biologics Via Microencapsulated Delivery With Likarda's Stella Vnook 9/30/2025

    A common challenge in administering cell therapies and other biologics-based treatments is sustaining delivery and bioavailability while protecting against degradation and off-target toxicities. In this episode of Supplier Horizons, host Tom von Gunden discusses with CEO Stella Vnook from platform technology developer Likarda methods for deploying hydrogel microencapsulation to safely route cells, proteins, and other biologic agents to therapeutic targets. These include long-acting formulations in oncology, immunology, and other chronic or rare diseases. 

  8. Understanding Oral Administration Challenges For Biologics 4/13/2026

    In this segment of the Drug Delivery Leader Live online event, Large Molecule Biologics Delivery: Aligning Formulations, Doses, And Devices, panelists John Higgins and Rubi Burlage respond to an audience question about oral delivery of biologic products. In commenting on efforts to deliver peptides, proteins, antibodies and other large molecules orally, Higgins and Burlage summarize key challenges to stability and bioavailability presented by the GI tract. 

  9. Setting The Strategic Direction For Advanced Therapy Products 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, underscores the importance of cascading business and regulatory strategies for advanced therapies and delivery products throughout the organization’s quality management systems. 

  10. DARPin-Delivered Radiotherapy With Molecular Partners And Orano Med 8/20/2025

    In this episode of In Combination, CEO Patrick Amstutz of Molecular Partners and CEO Arnaud Lesegretain of Orano Med join host Tom von Gunden in a discussion of using DARPins (Designed Ankyrin Repeat Proteins) as vector delivery platforms for high-affinity binding of radioisotopes to treat cancer. Using the example of small cell lung cancer. Patrick and Arnaud describe how DARPin-delivered radiotherapy can attack metastatic cancers while overcoming the targeting limitations of external beam radiation and of antibodies.